- Home
- MITQ vs SLXN Comparison
MITQ vs SLXN Comparison
Compare MITQ & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- SLXN
- Stock Information
- Founded
- MITQ N/A
- SLXN 2008
- Country
- MITQ United States
- SLXN Israel
- Employees
- MITQ N/A
- SLXN N/A
- Industry
- MITQ Telecommunications Equipment
- SLXN
- Sector
- MITQ Telecommunications
- SLXN
- Exchange
- MITQ Nasdaq
- SLXN NYSE
- Market Cap
- MITQ 5.5M
- SLXN 7.3M
- IPO Year
- MITQ 2021
- SLXN N/A
- Fundamental
- Price
- MITQ $0.66
- SLXN $0.81
- Analyst Decision
- MITQ
- SLXN Strong Buy
- Analyst Count
- MITQ 0
- SLXN 1
- Target Price
- MITQ N/A
- SLXN $5.00
- AVG Volume (30 Days)
- MITQ 9.8M
- SLXN 147.1K
- Earning Date
- MITQ 05-15-2025
- SLXN 08-21-2025
- Dividend Yield
- MITQ N/A
- SLXN N/A
- EPS Growth
- MITQ N/A
- SLXN N/A
- EPS
- MITQ N/A
- SLXN N/A
- Revenue
- MITQ $18,613,000.00
- SLXN N/A
- Revenue This Year
- MITQ N/A
- SLXN N/A
- Revenue Next Year
- MITQ N/A
- SLXN N/A
- P/E Ratio
- MITQ N/A
- SLXN N/A
- Revenue Growth
- MITQ N/A
- SLXN N/A
- 52 Week Low
- MITQ $0.50
- SLXN $0.58
- 52 Week High
- MITQ $1.55
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- MITQ 54.94
- SLXN N/A
- Support Level
- MITQ $0.62
- SLXN N/A
- Resistance Level
- MITQ $0.71
- SLXN N/A
- Average True Range (ATR)
- MITQ 0.07
- SLXN 0.00
- MACD
- MITQ 0.00
- SLXN 0.00
- Stochastic Oscillator
- MITQ 20.95
- SLXN 0.00
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.